SEARCH

SEARCH BY CITATION

References

  • 1
    Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 733.
  • 2
    Johansson JE, Holmberg L, Johansson S, et al: Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 1997; 277: 467471.
  • 3
    Pound CR, Partin AW, Epstein JI, et al: PSA following anatomical radical retropubic prostatectomy: An interim report. Urol Clin N Am 1997; 24: 395406.
  • 4
    Hanks GE, Hanlon AL, Schultheiss TE, et al: Conformal external beam treatment of prostate cancer. Urology 1997; 50: 8792.
  • 5
    Stromberg JS, Martinez AA, Horwitz EM, et al: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: Superior prostate specific antigen response compared to external beam treatment. Cancer J Sci Am 1997; 3: 346352.
  • 6
    Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of RTOG Protocol 85-31. J Clin Oncol 1997; 15: 10131021.
  • 7
    Mettlin CJ, Menck HR, Winchester DP, et al: A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results program. Cancer 1997; 79: 20522061.
  • 8
    Horwitz EM, Vicini FA, Ziaja EL, et al: Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996; 36: 565571.
  • 9
    Lee WR, Hanks GE, Schultheiss TE, et al: Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 1995; 13: 464469.
  • 10
    Schellhammer PF, El-Mahdi AM, Kuban DA, et al: Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and posttreat-ment nadir. Urol Clin N Am 1997; 24: 407414.
  • 11
    Zagars GK, Pollack A, von Eschenbach AC: Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997; 79: 13701380.
  • 12
    Lee WR, Hanks GE, Hanlon A: Increasing pro state-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 1997; 15: 230238.
  • 13
    Shipley WU, Prout GR Jr, Coachman NM, et al: Radiation therapy for localized prostate carcinoma: Experience at the Massachusetts General Hospital (1973–1981). NCI Monographs 1988; 7: 6773.
  • 14
    Zagars GK, von Eschenbach AC: Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiotherapy. Cancer 1993; 72: 538548.
  • 15
    Vicini FA, Horwitz EM, Gonzalez J, et al: Treatment options for localized prostate cancer based upon pretreatment serum prostate specific antigen levels. J Urol 1997; 158: 319325.
  • 16
    Zietman AL, Coen JJ, Dallow KC, et al: The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995; 32: 287292.
  • 17
    Leibel SA, Zelefsky MJ, Kutcher GJ, et al: Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase I dose-escalation study. J Urol 1994; 152: 17921798.
  • 18
    Kaplan ID, Cox RS, Bagshaw MA: Prostate specific antigen after external beam radiotherapy for prostatic cancer: Follow-up. J Urol 1993; 149: 519522.
  • 19
    American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 10351041.
  • 20
    McLaughlin PW, Sandier HM, Jiroutek MR: Prostate-specific antigen following prostate radiotherapy: How low can you go? J Clin Oncol 1996; 14: 28892892.
  • 21
    Forman JD, Porter AT: The experience with neutron irradiation in locally advanced adenocarci-noma of the prostate. Semin Urol Oncol 1997; 15: 239243.
  • 22
    Bentel GC, Marks LB, Sherhouse GW, et al: The effectiveness of immobilization during prostate irradiation. Int J Radiat Oncol Biol Phys 1995; 31: 143148.
  • 23
    Soffen EM, Hanks GE, Hwang CC, et al: Conformal static field therapy for low volume, low grade prostate cancer with rigid immobilization. Int J Radiat Oncol Biol Phys 1991; 20: 141146.
  • 24
    McShan DL, Fraass BA, Lichter AS: Full integration of the beam's eye view concept into computerized treatment planning. Int J Radiat Oncol Biol Phys 1990; 18: 14851494.
  • 25
    Boyer AL, Antonuk L, Fenster A, et al: A review of electronic portal imaging devices (EPIDs). Med Phys 1992; 19: 116.
  • 26
    Lattanzi J, McNeeley S, Pinover W, et al: A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys 1999; 43: 719725.
  • 27
    Frazier A, Du M, Wong J, et al: Dosimetric evaluation of the conformation of the multileaf collima-tor to irregularly shaped fields. Int J Radiat Oncol Biol Phys 1995; 33: 12291238.
  • 28
    Frazier A, Yan D, Du M, et al: Effects of treatment setup variation on the beam's eye view dosimetry for radiation therapy using the multileaf collimator versus the cerrobend block. Int J Radiat Oncol Biol Phys 1995; 33: 12471256.
  • 29
    LoSasso T, Chui CS, Kutcher GJ, et al: The use of a multileaf collimator for conformal radiotherapy of carcinomas of the prostate and nasopharynx. Int J Radiat Oncol Biol Phys 1993; 25: 161170.
  • 30
    Boyer AL, Yu CX: Intensity-modulated radiation therapy with dynamic multileaf collimators. Semin Radiat Oncol 1999; 9: 4859.
  • 31
    Fraass BA, Kessler ML, McShan DL, et al: Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy. Semin Radiat Oncol 1999; 9: 6077.
  • 32
    Verhey LJ: Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 1999; 9: 7898.
  • 33
    Hanks GE, Lee WR, Hanlon AL, et al: Conformal technique for dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen >10 ng/ml. Int J Radiat Oncol Biol Phys 1996; 35: 861868.
  • 34
    International Commission on Radiation Units and Measurements: Prescribing, recording, and reporting photon beam therapy, ICRU Report 50. Bethesda, MD: International Commission on Radiation Units and Measurements, 1993, pp. 316.
  • 35
    Wilder RB, Fone PD, Rademacher DE, et al: Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy. Int J Radiat Oncol Biol Phys 1997; 38: 737741.
  • 36
    Lee WR, Hanks GE, Hanlon AL, et al: Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996; 35: 251257.
  • 37
    Keyser D, Kupelian PA, Zippe CD, et al: Stage Tl-2 prostate cancer with pretreatment prostate-specific antigen level & pond; 10 ng/ml: Radiation therapy or surgery? Int J Radiat Oncol Biol Phys 1997; 38: 723729.
  • 38
    Hanks GE, Hanlon AL, Schultheiss TE, et al: Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998; 41: 501510.
  • 39
    Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491500.
  • 40
    Fukunaga-Johnson N, Sandier HM, McLaughlin PW, et al: Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 311317.
  • 41
    Roach III M, Meehan S, Kroll S, et al: Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 1996; 156: 17191723.
  • 42
    Fiveash JB, Hanks G, Roach M, et al: 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys. 2000 May l; 47 (2): 33542.
  • 43
    Pollack A, Zagars GK: External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39: 10111018.
  • 44
    Pinover WH, Hanlon AL, Horwitz EM, Hanks GE. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer. Int J Radiat Oncol Biol Phys 2000 Jun 1; 47 (3): 64954.
  • 45
    Shipley WU, Thames HD, Sandier HM, et al: Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999; 281: 15981604.
  • 46
    Forman JD, Kumar R, Haas G, et al: Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. Cancer Investigation 1995; 13: 815.
  • 47
    Zelefsky MJ, Harrison A: Neoadjuvant andro-gen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 1997; 49: 3845.
  • 48
    Yang FE, Chen GT, Ray P, et al: The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 10091017.
  • 49
    Zietman AL, Prince EA, Nakfoor BM, et al: Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38: 10671070.
  • 50
    Zietman AL, Nakfoor BM, Prince EA, et al: The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am 1997; 3: 3136.
  • 51
    Zietman AL, Prince EA, Nakfoor BM, et al: Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results. Urology 1997; 49: 7483.
  • 52
    Pollack A, Joon DL, Wu CS, et al: Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res 1997; 57: 24932500.
  • 53
    Pollack A, Zagars GK: Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit? Semin Radiat Oncol 1998; 8: 95106.
  • 54
    Garnick MB: Hormonal therapy in the management of prostate cancer: From Huggins to the present. Urology 1997; 49: 515.
  • 55
    Van Der Werf-Messing B, Sourek-Zikova V, Blonk DI: Localized advanced carcinoma of the prostate: Radiation therapy versus hormonal therapy. Int J Radiat Oncol Biol Phys 1976; 1: 10431048.
  • 56
    Neglia WJ, Hussey DH, Johnson DE: Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977; 2: 873883.
  • 57
    Zagars GK, Johnson DE, von Eschenbach AC, et al: Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long- term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988; 14: 10851091.
  • 58
    Pilepich MV, Krall JM, Sause WT, et al: Prognostic factors in carcinoma of the prostate-Analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 1987; 13: 339349.
  • 59
    Pilepich MV, Buzydlowski JW, John MJ, et al: Phase II trial of hormonal cytoreduction with mege-strol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 1995; 32: 175180.
  • 60
    Lawton C, Winter K, Murray K, et al: Updated Results of the Phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 Evaluating the Potential Benefit of Androgen Deprivation Following Standard Radiation Therapy for Unfavorable Prognosis Carcinoma of The Prostate (Meeting abstract). Proc Am Soc Clin Oncol 1999; 18: A1195.
  • 61
    Pilepich MV, Winter K, Roach M, et al: Phase III Radiation Therapy Oncology Group (RTOG) trial 86–10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998; 42: 177.
  • 62
    Bolla M, Gonzales D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295300.
  • 63
    Bolla M, Collette L, Gonzalez D, et al: Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study. Int J Radiat Oncol Biol Phys 1999; 45: 147.
  • 64
    Granfors T, Modig H, Damber JE, et al: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 1998; 159: 20302034.
  • 65
    Laramore GE, Krall JM, Thomas FJ, et al: Fast neutron radiotherapy for locally advanced prostate cancer. Final report of a Radiation Therapy Oncology Group randomized clinical trial. Am J Clin Oncol 1993; 16: 164167.
  • 66
    Russell KJ, Caplan RJ, Laramore GE, et al: Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: Results of a randomized prospective trial. Int J Radiat Oncol Biol Phys 1994; 28: 4754.
  • 67
    Russell KJ, Pajak TJ, Burnison CM, et al: Fast neutron radiotherapy vs. photon radiotherapy for locally-advanced adenocarcinoma of the prostate: Final report on a randomized clinical trial of the Neutron Therapy Collaborative Working Group. Int J Radiat Oncol Biol Phys 1999; 45: 168.
  • 68
    Forman JD, Duclos M, Sharma R, et al: Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: Preliminary estimates of the therapeutic ratio. Int J Radiat Oncol Biol Phys 1996; 35: 259266.
  • 69
    Shipley WU, Verhey LJ, Munzenrider JE, et al: Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32: 312.
  • 70
    Slater JD, Yonemoto LT, Rossi CJ Jr, et al: Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1998; 42: 299304.
  • 71
    Yonemoto LT, Slater JD, Rossi CJ Jr, et al: Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: Preliminary results of a phase I/II study. Int J Radiat Oncol Biol Phys 1997; 37: 2129.
  • 72
    Lawton CA, Won M, Pilepich MV, et al: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21: 935939.
  • 73
    Hanks GE: External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States. NCI Monographs 1988; 7: 7584.
  • 74
    Hanks GE, Teshima T, Pajak TF: 20 years of progress in radiation oncology: Prostate cancer. Semin Radiat Oncol 1997; 7: 114120.
  • 75
    Leibel SA, Hanks GE, Kramer S: Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984; 10: 401409.
  • 76
    Hanks GE, Schultheiss TE, Hunt MA, et al: Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995; 31: 2529.
  • 77
    Soffen EM, Hanks GE, Hunt MA, et al: Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992; 24: 485488.
  • 78
    Schultheiss TE, Lee WR, Hunt MA, et al: Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 311.
  • 79
    Sandier HM, McLaughlin PW, Ten Haken RK, et al: Three dimensional conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: 797801.
  • 80
    Michalski JM, Purdy JA, Winter K, et al: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46: 391402.
  • 81
    Kuban DA, El-Mahdi AM, Schellhammer PF: Prostate–specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32: 307316.
  • 82
    Pisansky TM, Cha SS, Earle JD, et al: Prostate-specific antigen as a pre-therapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11: 21582166.
  • 83
    Zagars GK, Pollack A: Radiation therapy for Tl and T2 prostate cancer: Pro state-specific antigen and disease outcome. Urology 1995; 45: 476483.
  • 84
    Zietman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151: 640645.
  • 85
    D'Amico AV, Whittington R, Malkowicz SB, et al: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131138.
  • 86
    Zagars GK, von Eschenbach AC, Ayala AG: Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993; 72: 17091725.
  • 87
    Crook JM, Bahadur YA, Robertson SJ, et al: Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997; 79: 8189.
  • 88
    Zietman AL, Tibbs MK, Dallow KC, et al: Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for Tl-2 adenocarcinoma of the prostate Radiother Oncol 1996; 40: 159162.
  • 89
    Bonin SR, Hanlon AL, Lee WR, et al: Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 1997; 79: 7580.
  • 90
    Pisansky TM, Kahn MJ, Rasp GM, et al: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997; 79: 337344.
  • 91
    Ben-Josef E, Shamsa F, Forman JD: Predicting the outcome of radiotherapy for prostate carcinoma. Cancer 1998; 82: 13341342.
  • 92
    Ziaja EL, Martinez AA, Horwitz EM, et al: Optimal reporting of treatment outcome after external beam radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42: 299.
  • 93
    Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997; 277: 14451451.
  • 94
    Kattan MW, Stapleton AM, Wheeler TM, et al: Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79: 528537.
  • 95
    Zagars GK, Pollack A, Kavadi VS, et al: Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32: 293306.
  • 96
    Movsas B, Hanlon AL, Teshima T, et al: Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer 1997; 80: 10931102.
  • 97
    Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110114.